AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

AZN.UK

10,390

-0.23%↓

GSK

1,411

-0.04%↓

Search

Indivior PLC

Fechado

1,112 4.51

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1047

Máximo

1114

Indicadores-chave

By Trading Economics

Rendimento

-19M

47M

Vendas

-33M

266M

P/E

Médio do Setor

330

40.527

EPS

0.41

Margem de lucro

17.669

Funcionários

1,030

EBITDA

-30M

76M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+21.14% upside

Dividendos

By Dow Jones

Próximos Ganhos

24 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

510M

1.3B

Abertura anterior

1107.49

Fecho anterior

1112

Indivior PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de jul. de 2025, 17:03 UTC

Grandes Movimentos do Mercado

Furniture Companies Rise on U.S. Trade Deal With Vietnam

2 de jul. de 2025, 15:18 UTC

Grandes Movimentos do Mercado

Mogo Shares Rally After Embrace of Bitcoin Into Holdings, Operations

2 de jul. de 2025, 23:45 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de jul. de 2025, 23:45 UTC

Conversa de Mercado

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2 de jul. de 2025, 23:40 UTC

Conversa de Mercado

Gold Edges Lower Amid Hopes for More Trade Deals -- Market Talk

2 de jul. de 2025, 21:01 UTC

Aquisições, Fusões, Aquisições de Empresas

AT&T Completes Sale of Entire Remaining 70% Stake in DIRECTV to TPG >T

2 de jul. de 2025, 21:01 UTC

Aquisições, Fusões, Aquisições de Empresas

AT&T and TPG Close DIRECTV Transaction

2 de jul. de 2025, 20:26 UTC

Ganhos

Rivian Stock Drops on Sales Decline. The Stakes Are High for the Rest of 2025. -- Barrons.com

2 de jul. de 2025, 20:22 UTC

Conversa de Mercado

Gold Rises Following Weak ADP Payroll Reading -- Market Talk

2 de jul. de 2025, 20:13 UTC

Conversa de Mercado

Oil Price Expectations Stable in Dallas Fed Survey -- Market Talk

2 de jul. de 2025, 19:09 UTC

Conversa de Mercado

Oil Futures Bounce in Defiance of Downbeat Data -- Market Talk

2 de jul. de 2025, 19:08 UTC

Conversa de Mercado

Dollar Trims Gains as Investors Brace for Cooling Jobs Market -- Market Talk

2 de jul. de 2025, 19:01 UTC

Conversa de Mercado

U.S. Natural Gas Ticks Up Ahead of Storage Data -- Market Talk

2 de jul. de 2025, 18:08 UTC

Conversa de Mercado

Fossil Fuels Rule Energy Roost As U.S. Marks Independence -- Market Talk

2 de jul. de 2025, 17:06 UTC

Aquisições, Fusões, Aquisições de Empresas

BCE: Maple Leafs, Raptors Rights Access Through Long-Term Agreement With Rogers, Subject to League Approvals

2 de jul. de 2025, 17:05 UTC

Aquisições, Fusões, Aquisições de Empresas

BCE: Access to Content Rights for Toronto Maple Leafs, Toronto Raptors on TSN Secured Through 2043/2044 Season

2 de jul. de 2025, 17:04 UTC

Aquisições, Fusões, Aquisições de Empresas

BCE: Proceeds of MLSE Stake Sale to Support Financing of Acquisition of Ziply Fiber

2 de jul. de 2025, 17:04 UTC

Aquisições, Fusões, Aquisições de Empresas

BCE Inc. Concludes Sale of Minority Stake in Maple Leaf Sports & Entertainment

2 de jul. de 2025, 17:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Rogers Communications: Now Largest Owner With 75% Interest in Maple Leaf Sports & Entertainment

2 de jul. de 2025, 17:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Rogers Communications Closes Deal to Buy BCE's 37.5% Stake in Maple Leaf Sports & Entertainment for C$4.7B

2 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

2 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Cushing Crude Stock Slide Keeps Bid in WTI -- Market Talk

2 de jul. de 2025, 16:20 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

2 de jul. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

2 de jul. de 2025, 16:11 UTC

Conversa de Mercado

Copper Prices Hold Higher on Supply Disruption, Tariff Uncertainty -- Market Talk

2 de jul. de 2025, 16:09 UTC

Conversa de Mercado

Gold Futures Rise, Recouping Some Losses -- Market Talk

2 de jul. de 2025, 15:59 UTC

Ganhos

These Stocks Are Moving the Most Today: Tesla, Centene, Apple, Adobe, Rigetti Computing, Greenbrier, and More -- Barrons.com

2 de jul. de 2025, 15:17 UTC

Conversa de Mercado

Oil Market to Keep Close Watch on U.S. Payrolls -- Market Talk

2 de jul. de 2025, 15:08 UTC

Conversa de Mercado

Luxury Sector Should Report a Slowdown -- Market Talk

2 de jul. de 2025, 15:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Glencore: Merger of Viterra With Bunge Global Closed

Comparação entre Pares

Variação de preço

Indivior PLC Previsão

Preço-alvo

By TipRanks

21.14% parte superior

Previsão para 12 meses

Média 1,313.17 GBX  21.14%

Máximo 1,602.789 GBX

Mínimo 947.103 GBX

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Indivior PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

4

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.